Kancera and partner revise the patent strategy for the HDAC project


This is a translation of a press release in Swedish published in Stockholm 2019-11-22

Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors for the treatment of pain and inflammation. The companies have now decided for strategic reasons to withdraw a patent application for a series of HDAC inhibitors in order to submit a new supplementary application at a later stage. Existing cooperation agreements have been supplemented in accordance with this new strategy to allow both parties to enjoy the benefits of this revised patent strategy.

As previously announced, under the agreement for all preclinical research, Grünenthal is responsible for developing drug candidates from two of Kancera’s series of HDAC inhibitors and is granted the right to acquire these substances for further clinical development into marketed products. The HDAC project is continuing in accordance with the cooperation agreement.

“Constantly reviewing and strengthening the patent strategy is a natural part of the work in this type of drug development project. We look forward to the continued development of the HDAC project with the goal of achieving a breakthrough in the fight against nerve pain,” says Thomas Olin, CEO for Kancera AB.

About HDAC inhibitors

HDAC inhibitors have been shown to affect disease processes such as inflammation, pain and cancer. Preclinical tests have shown that Kancera’s substances have a high degree of selectivity and efficacy against HDAC6 within the family of HDAC enzymes. They also have a good ability to be absorbed into the body after oral administration, which together makes them interesting starting points for the development of new drugs for several types of diseases.

About Kancera
Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study during the first half of 2020. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell’s ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, info@fnca.se) is the company’s Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB. 

For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

We welcome you to visit our home-page: www.kancera.com